Status
Conditions
Treatments
About
The purpose of this study is to examine how a multimodality (having or using a variety of methods to do something) exercise intervention may improve survival, function, and quality of life in participants with advanced lung cancer.
Full description
This study is a randomized control trial at a single institution comparing advanced lung cancer patients undergoing supervised home-based exercise program versus usual care. The intervention is a supervised home-based exercise program that will be coordinated by the MOVE program. The regimen will be 12 weeks in duration, three times a week, and administered by a trained professional virtually.
Participants will be randomized 1:1 to the exercise or usual care arm. Participants will be stratified on baseline frailty by the SPPB.
Primary Objective To compare changes patient-reported fatigue (by FACT-F survey) from baseline to post-intervention in patients with locally advanced and advanced lung cancer receiving maintenance immunotherapy undergoing a supervised home-based exercise program versus usual care.
Secondary Objectives
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age ≥ 18 years
Known diagnosis of locally advanced (stage III) or metastatic NSCLC
Patient is currently receiving maintenance immunotherapy for at least 1 month and planned for at least 3 additional months of therapy
Patient is willing and able to participate in a supervised home-based exercise program as determined by the MOVE program
a.Participants must have internet access and equipment to participate in virtual exercise
ECOG performance status of 0-2
Exclusion criteria
Already meeting exercise guidelines and participating in at least 150 minutes of moderate or vigorous exercise per IPAQ
Unable to participate in the supervised home-based exercise program as determined by the MOVE program
Medical co-morbidities that preclude patient from participating in supervised exercise, including but not limited to:
Primary purpose
Allocation
Interventional model
Masking
100 participants in 2 patient groups
Loading...
Central trial contact
Tarah J Ballinger, MD; Malori Pojar
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal